In silico research in drug discovery.
Target and lead discovery constitute the main components of today's early pharmaceutical research. The aim of target discovery is the identification and validation of suitable drug targets for therapeutic intervention, whereas lead discovery identifies novel chemical molecules that act on those targets. With the near completion of the human genome sequencing, bioinformatics has established itself as an essential tool in target discovery and the in silico analysis of gene expression and gene function are now an integral part of it, facilitating the selection of the most relevant targets for a disease under study. In lead discovery, advances in chemoinformatics have led to the design of compound libraries in silico that can be screened virtually. Moreover, computational methods are being developed to predict the drug-likeness of compounds. Thus, drug discovery is already on the road towards electronic R&D.
Terstappen
G C
GC
Biology Dept., Glaxo Wellcome Medicines Research Centre, Via A. Fleming 4, 37135, Verona, Italy. gct66554@glaxowellcome.co.uk
Reggiani
A
A
D019295:Computational Biology; D015195:Drug Design; D020869:Gene Expression Profiling; D015894:Genome, Human; D006801:Humans; D019151:Peptide Library
D019151:Peptide Library